DATA GRAPHICS | Data Byte
Survodutide leads GLP-1s in MASH
Phase II data for dual GLP-1/glucagon agonist from BI, Zealand suggest best-in-class potential in metabolic dysfunction-associated steatohepatitis
February 27, 2024 12:40 AM UTC
Boehringer Ingelheim GmbH may have found its niche for survodutide in MASH as Phase II data put it ahead of other GLP-1-based rivals.
Tirzepatide from Eli Lilly and Co. (NYSE:LLY) and semaglutide from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) are dominating the market commercially in Type II diabetes and obesity; however, they appear to have stiff competition in metabolic dysfunction-associated steatohepatitis from survodutide. MASH is also known as non-alcoholic steatohepatitis (NASH)...